Surrozen (SRZN) Income towards Parent Company (2020 - 2026)
Surrozen (SRZN) recorded quarterly Income towards Parent Company of -$9.5 million in Q1 2026, up 19.47% quarter-over-quarter from -$11.9 million in Q4 2025, and down 3.12% on a YoY basis from -$9.9 million in Q1 2025.
Surrozen (SRZN) Income towards Parent Company (2020 - 2026) Analysis & Trends
Surrozen's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$9.5 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 3.12% year-over-year to -$9.5 million; the TTM figure through Mar 2026 stood at -$39.4 million (down 61.61% YoY), while the FY2025 annual figure was -$39.1 million, down 63.85% from the prior year.
- Income towards Parent Company was -$9.5 million for Q1 2026 at Surrozen, up from -$11.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $1.7 million in Q3 2024 to a low of -$14.4 million in Q1 2022.
- Historically, Income towards Parent Company has averaged -$9.4 million across 5 years, with a median of -$9.5 million in 2026.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company surged 115.8% in 2024, then plunged 699.76% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$1.7 million in 2022, then plunged by 443.66% to -$9.2 million in 2023, then climbed by 10.96% to -$8.2 million in 2024, then slumped by 44.44% to -$11.9 million in 2025, then grew by 19.47% to -$9.5 million in 2026.
- The last three Income towards Parent Company figures came in at -$9.5 million (Q1 2026), -$11.9 million (Q4 2025), and -$10.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.54 Mn |
| Dec 31, 2025 | -11.85 Mn |
| Sep 30, 2025 | -9.97 Mn |
| Jun 30, 2025 | -7.99 Mn |
| Mar 31, 2025 | -9.26 Mn |
| Dec 31, 2024 | -8.21 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | -8.56 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -9.22 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -9.65 Mn |
| Mar 31, 2023 | -14.05 Mn |
| Dec 31, 2022 | -1.70 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -14.01 Mn |
| Mar 31, 2022 | -14.44 Mn |
| Dec 31, 2021 | -14.95 Mn |
| Sep 30, 2021 | -13.69 Mn |
| Jun 30, 2021 | -12.65 Mn |